Pen needles are used by providers to treat asthma attacks and severe allergic reactions
J Endocrinol 75 , 305316 (1977)
Side-by-side compound comparison Receptor targets Tirzepatide GLP-1 + GIP (dual) Semaglutide GLP-1 only Retatrutide GLP-1 + GIP + Glucagon (triple) Half-life Tirzepatide ~5 days Semaglutide ~7 days Retatrutide ~6 days Dosing frequency Tirzepatide Once weekly Semaglutide Once weekly Retatrutide Once weekly Max studied dose Tirzepatide 15 mg / week Semaglutide 2.4 mg / week (Wegovy) Retatrutide 12 mg / week Peak weight loss Tirzepatide 22.5% (SURMOUNT-1, 72 wk) Semaglutide 15.8% (STEP-1, 68 wk) Retatrutide 24.2% (Phase 2, 48 wk) FDA status (June 2026) Tirzepatide Approved (T2D, obesity, OSA) Semaglutide Approved (T2D, obesity, CV risk) Retatrutide Investigational Phase 3 Head-to-head Tirzepatide 20.2% vs semaglutide 13.7% (SURMOUNT-5) Semaglutide Retatrutide Not yet head-to-head vs tirzepatide HFpEF benefit Tirzepatide Yes (SUMMIT, HR 0.62) Semaglutide Yes (STEP-HFpEF) Retatrutide Not yet studied Unique advantage Tirzepatide Best-in-class FDA-approved efficacy
+ Chronic Fatigue Syndrome (CFS) + Autoimmune Disorders (Rheumatoid Arthritis, Lupus, Hashimotos) + Thyroid Imbalances (Hypothyroidism, Hyperthyroidism) + Digestive Disorders (IBS, Crohns Disease, SIBO, Leaky Gut) + Migraines and Chronic Headaches + Mental Health Concerns (Anxiety, Depression, ADHD) + Weight Gain and Obesity + Food Sensitivities and Allergies + Diabetes Type 2 and Insulin Resistance + Heart Disease Risk Factors (Cholesterol, Hypertension) + Acne and Skin Conditions (Eczema, Psoriasis) + Chronic Infections (Lyme Disease, Epstein-Barr, Candida) + Toxicity and Heavy Metal Exposure + Gut Health Disorders (Constipation, Bloating, Indigestion) + Celiac Disease and Gluten Sensitivity + Chronic Allergies (Seasonal, Environmental, Food) Here's the latest Get insights from our office on the latest treatments, trends and topics
